Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement
Open Access
- 26 May 2010
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (S1) , 1-4
Abstract
This paper will evaluate various topics related to chemotherapy-induced nausea and vomiting. The results published reflect a consensus conference convened in Perugia, Italy. The topics discussed include antiemetic therapy of multiple-day chemotherapy, high-dose chemotherapy, and rescue antiemetics.Keywords
This publication has 21 references indexed in Scilit:
- Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapyEuropean Journal of Cancer, 2009
- American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and ChallengesJournal of Clinical Oncology, 2008
- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupportive Care in Cancer, 2007
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapyBritish Journal of Cancer, 2006
- A Randomized, Multicenter, Open-Label Comparison of the Antiemetic Efficacy of Dolasetron Versus Ondansetron for the Prevention of Nausea and Vomiting During High-Dose Myeloablative ChemotherapySupportive Cancer Therapy, 2005
- Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statementSupportive Care in Cancer, 2004
- Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell supportBone Marrow Transplantation, 2001
- The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumoursBritish Journal of Cancer, 2001
- Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapyCancer, 1992
- Superiority of Nabilone over Prochlorperazine as an Antiemetic in Patients Receiving Cancer ChemotherapyNew England Journal of Medicine, 1979